Persistence of Clinically Significant Portal Hypertension After Eradication of Hepatitis C Virus in Patients With Advanced Cirrhosis
- PMID: 32386053
- DOI: 10.1093/cid/ciaa502
Persistence of Clinically Significant Portal Hypertension After Eradication of Hepatitis C Virus in Patients With Advanced Cirrhosis
Abstract
This prospective study of 34 patients with HCV cirrhosis (17 HIV positive) with baseline clinically significant portal hypertension (CSPH; HVPG ≥10 mmHg) and SVR after DAA therapy showed that disappearance of CSPH (primary endpoint) is a rare event (6/18 patients; 18%), indicating a persistent risk of clinical progression or death.
Keywords: HCV; cirrhosis; direct-acting antiviral agents; eradication; portal hypertension.
© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.
Comment in
-
Hepatitis C Virus Cure Is the Start of the End for Patients With Advanced Fibrosis/Cirrhosis.Clin Infect Dis. 2020 Dec 17;71(10):2730-2731. doi: 10.1093/cid/ciaa509. Clin Infect Dis. 2020. PMID: 32386202 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical